Invasive Fungal Infections in the Era of Biologics

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

With the advent and widespread use of immunomodulating biologic agents, emerging invasive fungal infections are reported increasingly. To date there is no reliable method to screen patients before starting anti-tumor necrosis factor (TNF) therapy to predict their risk for acquiring fungal infections, partly because most of these infections are de novo infections. Patients should be counseled about avoiding high-risk activities that are associated with the endemic mycosis in their geographic areas. Physicians should keep a high level of suspicion for endemic fungal infections when patients receiving anti-TNF therapy or other biologics present with pulmonary or systemic infections. Rapid diagnosis and initiation of antifungal therapy are of utmost importance.

Original languageEnglish (US)
Pages (from-to)279-286
Number of pages8
JournalClinics in Chest Medicine
Volume30
Issue number2
DOIs
StatePublished - Jun 1 2009

Fingerprint

Mycoses
Biological Products
Tumor Necrosis Factor-alpha
Infection
Biological Factors
Therapeutics
Physicians
Lung
Invasive Fungal Infections

Keywords

  • Adalimumab
  • Aspergillosis
  • Coccidioidomycosis
  • Etanercept
  • Histoplasmosis
  • Infliximab
  • Invasive mycoses
  • TNF-alpha

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Invasive Fungal Infections in the Era of Biologics. / Arnold, Tamra M.; Sears, Catherine R.; Hage, Chadi A.

In: Clinics in Chest Medicine, Vol. 30, No. 2, 01.06.2009, p. 279-286.

Research output: Contribution to journalReview article

@article{a6827cd5e43843e483abdd580da92a29,
title = "Invasive Fungal Infections in the Era of Biologics",
abstract = "With the advent and widespread use of immunomodulating biologic agents, emerging invasive fungal infections are reported increasingly. To date there is no reliable method to screen patients before starting anti-tumor necrosis factor (TNF) therapy to predict their risk for acquiring fungal infections, partly because most of these infections are de novo infections. Patients should be counseled about avoiding high-risk activities that are associated with the endemic mycosis in their geographic areas. Physicians should keep a high level of suspicion for endemic fungal infections when patients receiving anti-TNF therapy or other biologics present with pulmonary or systemic infections. Rapid diagnosis and initiation of antifungal therapy are of utmost importance.",
keywords = "Adalimumab, Aspergillosis, Coccidioidomycosis, Etanercept, Histoplasmosis, Infliximab, Invasive mycoses, TNF-alpha",
author = "Arnold, {Tamra M.} and Sears, {Catherine R.} and Hage, {Chadi A.}",
year = "2009",
month = "6",
day = "1",
doi = "10.1016/j.ccm.2009.02.007",
language = "English (US)",
volume = "30",
pages = "279--286",
journal = "Clinics in Chest Medicine",
issn = "0272-5231",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Invasive Fungal Infections in the Era of Biologics

AU - Arnold, Tamra M.

AU - Sears, Catherine R.

AU - Hage, Chadi A.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - With the advent and widespread use of immunomodulating biologic agents, emerging invasive fungal infections are reported increasingly. To date there is no reliable method to screen patients before starting anti-tumor necrosis factor (TNF) therapy to predict their risk for acquiring fungal infections, partly because most of these infections are de novo infections. Patients should be counseled about avoiding high-risk activities that are associated with the endemic mycosis in their geographic areas. Physicians should keep a high level of suspicion for endemic fungal infections when patients receiving anti-TNF therapy or other biologics present with pulmonary or systemic infections. Rapid diagnosis and initiation of antifungal therapy are of utmost importance.

AB - With the advent and widespread use of immunomodulating biologic agents, emerging invasive fungal infections are reported increasingly. To date there is no reliable method to screen patients before starting anti-tumor necrosis factor (TNF) therapy to predict their risk for acquiring fungal infections, partly because most of these infections are de novo infections. Patients should be counseled about avoiding high-risk activities that are associated with the endemic mycosis in their geographic areas. Physicians should keep a high level of suspicion for endemic fungal infections when patients receiving anti-TNF therapy or other biologics present with pulmonary or systemic infections. Rapid diagnosis and initiation of antifungal therapy are of utmost importance.

KW - Adalimumab

KW - Aspergillosis

KW - Coccidioidomycosis

KW - Etanercept

KW - Histoplasmosis

KW - Infliximab

KW - Invasive mycoses

KW - TNF-alpha

UR - http://www.scopus.com/inward/record.url?scp=64249138632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249138632&partnerID=8YFLogxK

U2 - 10.1016/j.ccm.2009.02.007

DO - 10.1016/j.ccm.2009.02.007

M3 - Review article

C2 - 19375634

AN - SCOPUS:64249138632

VL - 30

SP - 279

EP - 286

JO - Clinics in Chest Medicine

JF - Clinics in Chest Medicine

SN - 0272-5231

IS - 2

ER -